
Nomenclature scheme for gene products
Approved by the USAN Council
July 2006
I. Scope
Scheme would apply only to non-cellular products produced by insertion of genetic material (transgene) into a vector (virus or plasmid) and where altered genetic material is administered to patients as a biologic drug.
II. Elements of name
Three elements have been identified that are important in distinguishing a gene therapy drug and conveying safety information to the user physician. These include:
Additional nomenclature elements would be a fantasy syllable(s) that serves as a unique identifier for the molecular entity and a stem indicating the gene therapy class of products or the ability of the vector to replicate. Based on these elements, the following is proposed:
First word: corresponds to the gene component
Prefix: Fantasy element to provide unique identification; to contribute to the distinct name
Infix: Element to denote the gene’s mechanism of action (pharmacologic class) such as:
-lim- [immunomodulator]
-tusu- [tumor supression]
-ermin- [growth factor]
-kin- [interleukins]
-cept- [receptors]
Stem: Element to indicate gene
-gene
Second word: corresponds to the vector component
Prefix: Fantasy element to provide unique identification; to contribute to the distinct name
Infix: Element to denote the type of viral vector such as
-lenti- [lentivirus]
-retro- [other retro viruses]
-adeno- [adenovirus]
-herpa- [herpes virus]
-parvo- [adeno-associated virus (parvovirdae dependovirus)]
-cana- [canarypox virus]
-vari- [vaccinia virus]
-morbilli- [measles (paramyxoviridae morbillivirus)]
Stem: Element to identify type of vector
-vec [non-replicating viral vector]
-repvec [replicating viral vector]
-plasmid [plasmid vector]